TOKYO--(BUSINESS WIRE)--Zeria Pharmaceutical (TOKYO:4559) (ISIN: JP3428850006) announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; “acotiamide”) for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract. Z-338 was developed by Zeria Pharmaceutical Co., Ltd based in Tokyo, and is currently being co-developed by Astellas Pharma Inc based in Tokyo. Acotiamide is expected to be the first-in-class for FD diagnosed by the Rome ?, and will be launched in Japan ahead of the rest of the world.
